Gender differences in quality of life and the course of schizophrenia: national study.
Epidemiology
Manchester Short Assessment of Quality of Life
females
males
national registry data
Journal
BJPsych open
ISSN: 2056-4724
Titre abrégé: BJPsych Open
Pays: England
ID NLM: 101667931
Informations de publication
Date de publication:
01 Feb 2022
01 Feb 2022
Historique:
entrez:
1
2
2022
pubmed:
2
2
2022
medline:
2
2
2022
Statut:
epublish
Résumé
Evidence from various sources suggests that females with schizophrenia tend to report lower quality of life than males with schizophrenia despite having a less severe course of the disorder. However, studies have not examined this directly. To examine gender differences in the association between quality of life and the risk of subsequent psychiatric hospital admissions in a national sample with schizophrenia. The sample consisted of 989 (60.90%) males and 635 (39.10%) females with an ICD-10 diagnosis of schizophrenia. Quality of life was assessed and scored using the Manchester Short Assessment of Quality of Life. The course of schizophrenia was assessed from the number of psychiatric hospital admissions. Participants completed the quality of life assessment and were then followed up for 18-months for subsequent psychiatric admissions. Hazard ratios (HR) from Cox proportional hazards regression models were estimated unadjusted and adjusted for covariates (age at schizophrenia onset and birth year). Analyses were computed for males and females separately, as well as for the entire cohort. A subsample of 93 males and 55 females was admitted to a psychiatric hospital during follow-up. Higher quality of life scores were significantly (P < 0.05) associated with a reduced risk of subsequent admissions among males (unadjusted: HR = 0.96, 95% CI 0.93-0.99; adjusted HR = 0.96, 95% CI 0.93-0.99) but not among females (unadjusted: HR = 0.97, 95% CI 0.93-1.02; adjusted HR = 0.97, 95% CI 0.93-1.02). Quality of life in schizophrenia is a gender-specific construct and should be considered as such in clinical practice and future research.
Sections du résumé
BACKGROUND
BACKGROUND
Evidence from various sources suggests that females with schizophrenia tend to report lower quality of life than males with schizophrenia despite having a less severe course of the disorder. However, studies have not examined this directly.
AIMS
OBJECTIVE
To examine gender differences in the association between quality of life and the risk of subsequent psychiatric hospital admissions in a national sample with schizophrenia.
METHOD
METHODS
The sample consisted of 989 (60.90%) males and 635 (39.10%) females with an ICD-10 diagnosis of schizophrenia. Quality of life was assessed and scored using the Manchester Short Assessment of Quality of Life. The course of schizophrenia was assessed from the number of psychiatric hospital admissions. Participants completed the quality of life assessment and were then followed up for 18-months for subsequent psychiatric admissions. Hazard ratios (HR) from Cox proportional hazards regression models were estimated unadjusted and adjusted for covariates (age at schizophrenia onset and birth year). Analyses were computed for males and females separately, as well as for the entire cohort.
RESULTS
RESULTS
A subsample of 93 males and 55 females was admitted to a psychiatric hospital during follow-up. Higher quality of life scores were significantly (P < 0.05) associated with a reduced risk of subsequent admissions among males (unadjusted: HR = 0.96, 95% CI 0.93-0.99; adjusted HR = 0.96, 95% CI 0.93-0.99) but not among females (unadjusted: HR = 0.97, 95% CI 0.93-1.02; adjusted HR = 0.97, 95% CI 0.93-1.02).
CONCLUSIONS
CONCLUSIONS
Quality of life in schizophrenia is a gender-specific construct and should be considered as such in clinical practice and future research.
Identifiants
pubmed: 35101158
doi: 10.1192/bjo.2022.3
pii: S2056472422000035
pmc: PMC8867859
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e35Subventions
Organisme : Israel Ministry of Health the Laszlo N. Tauber Family Foundation
Références
Acta Psychiatr Scand Suppl. 2000;(407):58-62
pubmed: 11261642
J Clin Psychiatry. 2021 May 18;82(4):
pubmed: 34010524
Schizophr Res. 1991 Jan-Feb;4(1):1-9
pubmed: 2009251
Schizophr Res. 2001 Sep 1;51(2-3):171-80
pubmed: 11518637
Br J Psychiatry. 2000 Jul;177:42-6
pubmed: 10945087
Am J Psychiatry. 2003 Jul;160(7):1209-22
pubmed: 12832232
Expert Rev Pharmacoecon Outcomes Res. 2013 Jun;13(3):343-9
pubmed: 23763531
Psychol Med. 2005 Nov;35(11):1655-65
pubmed: 16219123
Ther Adv Psychopharmacol. 2013 Aug;3(4):200-18
pubmed: 24167693
Schizophr Bull. 1990;16(2):309-18
pubmed: 2374886
Schizophr Res. 2007 Mar;91(1-3):254-8
pubmed: 17293084
Schizophr Res. 2011 Mar;126(1-3):184-91
pubmed: 21093220
Psychoneuroendocrinology. 2003 Apr;28 Suppl 2:17-54
pubmed: 12650680
Int Rev Psychiatry. 2010;22(5):417-28
pubmed: 21047156
Schizophr Res. 2012 Apr;136(1-3):13-8
pubmed: 22326516
Psychol Med. 1998 Jan;28(1):165-72
pubmed: 9483693
Schizophr Bull. 2007 Sep;33(5):1225-37
pubmed: 17204532
Compr Psychiatry. 2005 Jan-Feb;46(1):38-42
pubmed: 15714193
Schizophr Res. 2006 Dec;88(1-3):96-101
pubmed: 16962742
Psychol Med. 2016 Mar;46(4):855-63
pubmed: 26619765
Eur Psychiatry. 2018 Sep;53:100-106
pubmed: 29957368
Schizophr Bull. 2010 May;36(3):624-32
pubmed: 18849294
Schizophr Bull. 1992;18(2):209-15
pubmed: 1377833
Int J Soc Psychiatry. 1999 Spring;45(1):7-12
pubmed: 10443245
Acta Psychiatr Scand Suppl. 2000;(407):44-8
pubmed: 11261639
J Psychiatry Neurosci. 1997 Jul;22(4):231-4
pubmed: 9262044
Schizophr Res. 2012 Mar;135(1-3):187-91
pubmed: 22260965
Int Rev Psychiatry. 2015;27(4):345-53
pubmed: 25865480
Psychiatry Res. 2009 Jun 30;168(1):11-7
pubmed: 19346003
Compr Psychiatry. 1994 Sep-Oct;35(5):361-5
pubmed: 7995028
Acta Psychiatr Scand Suppl. 2000;401:3-38
pubmed: 10887978
Schizophr Res. 2016 Oct;176(2-3):387-391
pubmed: 27328889
PLoS One. 2020 Feb 24;15(2):e0229514
pubmed: 32092123